Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Ned Tijdschr Geneeskd ; 1662022 11 14.
Artículo en Holandés | MEDLINE | ID: mdl-36633070

RESUMEN

The use of medication contributes significantly to the total CO2 emission caused by the public health sector. Conservative estimates reveal that the amount of medication distributed by public pharmacies but is wasted unused equalizes a total amount of 100 million euro. Data regarding medication waste in hospitals is not yet available. Besides costs, wasting unused medication also has an enormous ecological impact. We analysed the stream of medication waste in our hospital and tried to reduce this by addressing the main causes. Our medication distribution process is mainly based on financial and quality based decisions, but should impact on planetary health not also be included? To realize this, though, both ecotoxicologic data as well as information related to environmental impact of medication production should be available and easily accessible.


Asunto(s)
Medicamentos bajo Prescripción , Humanos , Costos y Análisis de Costo , Hospitales , Caquexia
2.
Neurochem Int ; 57(8): 948-57, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20946930

RESUMEN

We have investigated effects of continuous SSRI administration and abrupt discontinuation on biochemical and behavioral indices of rat brain serotonin function, and attempted to identify underlying mechanisms. Biochemistry of serotonin was assessed with brain tissue assays and microdialysis; behavior was assessed as the acoustic startle reflex. Long-term SSRI administration to rats reduced the content of 5-HT and its main metabolite shortly after inhibition of 5-HT synthesis in many brain areas with more than 50%. Turnover was not appreciably decreased, but significantly increased within 48h of drug discontinuation. The microdialysis experiments indicate that neuronal release of 5-HT depends strongly on new synthesis and emphasize the role of 5-HT(1B) receptors in the regulation of these processes. Discontinuation of the SSRI rapidly increased behavioral reactivity to the external stimulus. Additional startle experiments suggest that the increased reactivity is more likely related to the reduced extracellular 5-HT levels than to impaired synthesis. The combination of the marked reduction of serotonin content and limited synthesis may destabilize brain serotonin transmission during long-term SSRI treatment. These combined effects may compromise the efficacy of an SSRI therapy and facilitate behavioral changes following non-compliance.


Asunto(s)
Conducta Animal/efectos de los fármacos , Conducta Animal/fisiología , Citalopram/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Serotonina/deficiencia , Síndrome de Abstinencia a Sustancias/metabolismo , Animales , Química Encefálica/efectos de los fármacos , Química Encefálica/fisiología , Trastorno Depresivo/tratamiento farmacológico , Trastorno Depresivo/metabolismo , Trastorno Depresivo/psicología , Masculino , Ratas , Ratas Wistar , Serotonina/biosíntesis , Síndrome de Abstinencia a Sustancias/psicología , Factores de Tiempo
3.
PLoS One ; 4(8): e6797, 2009 Aug 27.
Artículo en Inglés | MEDLINE | ID: mdl-19710918

RESUMEN

BACKGROUND: Serotonin (5-HT) is a neurotransmitter with important roles in the regulation of neurobehavioral processes, particularly those regulating affect in humans. Drugs that potentiate serotonergic neurotransmission by selectively inhibiting the reuptake of serotonin (SSRIs) are widely used for the treatment of psychiatric disorders. Although the regulation of serotonin synthesis may be an factor in SSRI efficacy, the effect of chronic SSRI administration on 5-HT synthesis is not well understood. Here, we describe effects of chronic administration of the SSRI citalopram (CIT) on 5-HT synthesis and content in the mouse forebrain. METHODOLOGY/PRINCIPAL FINDINGS: Citalopram was administered continuously to adult male C57BL/6J mice via osmotic minipump for 2 days, 14 days or 28 days. Plasma citalopram levels were found to be within the clinical range. 5-HT synthesis was assessed using the decarboxylase inhibition method. Citalopram administration caused a suppression of 5-HT synthesis at all time points. CIT treatment also caused a reduction in forebrain 5-HIAA content. Following chronic CIT treatment, forebrain 5-HT stores were more sensitive to the depleting effects of acute decarboxylase inhibition. CONCLUSIONS/SIGNIFICANCE: Taken together, these results demonstrate that chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain. Furthermore, our results indicate that chronic 5-HT reuptake inhibition renders 5-HT brain stores more sensitive to alterations in serotonin synthesis. These results suggest that the regulation of 5-HT synthesis warrants consideration in efforts to develop novel antidepressant strategies.


Asunto(s)
Antidepresivos de Segunda Generación/farmacología , Citalopram/farmacología , Prosencéfalo/efectos de los fármacos , Serotonina/biosíntesis , Animales , Antidepresivos de Segunda Generación/sangre , Citalopram/sangre , Masculino , Ratones , Ratones Endogámicos C57BL , Prosencéfalo/metabolismo
4.
PLoS One ; 2(12): e1360, 2007 Dec 26.
Artículo en Inglés | MEDLINE | ID: mdl-18159243

RESUMEN

Schizophrenia is often associated with emotional blunting--the diminished ability to respond to emotionally salient stimuli--particularly those stimuli representative of negative emotional states, such as fear. This disturbance may stem from dysfunction of the amygdala, a brain region involved in fear processing. The present article describes a novel animal model of emotional blunting in schizophrenia. This model involves interfering with normal fear processing (classical conditioning) in rats by means of acute ketamine administration. We confirm, in a series of experiments comprised of cFos staining, behavioral analysis and neurochemical determinations, that ketamine interferes with the behavioral expression of fear and with normal fear processing in the amygdala and related brain regions. We further show that the atypical antipsychotic drug clozapine, but not the typical antipsychotic haloperidol nor an experimental glutamate receptor 2/3 agonist, inhibits ketamine's effects and retains normal fear processing in the amygdala at a neurochemical level, despite the observation that fear-related behavior is still inhibited due to ketamine administration. Our results suggest that the relative resistance of emotional blunting to drug treatment may be partially due to an inability of conventional therapies to target the multiple anatomical and functional brain systems involved in emotional processing. A conceptual model reconciling our findings in terms of neurochemistry and behavior is postulated and discussed.


Asunto(s)
Emociones , Modelos Animales , Psicología del Esquizofrénico , Animales , Conducta Animal , Condicionamiento Clásico , Dopamina/metabolismo , Miedo , Ácido Glutámico/metabolismo , Masculino , Ratas , Ratas Sprague-Dawley
5.
Artículo en Inglés | MEDLINE | ID: mdl-15961207

RESUMEN

The authors have investigated 5-HT 1B receptor function in prefrontal cortex and dorsal hippocampus as well as the HPA axis response after subchronic (24 h) and chronic (15 days) treatment with the SSRI citalopram. All experiments were carried out in presence of citalopram to prevent rapid resensitization of the 5-HT(1B) receptors. Moreover, this more closely resembles the clinical situation. The concentration of citalopram was measured in both brain areas to ensure comparable levels in the different treatment groups. Using microdialysis, the authors found that under those conditions the effect of the 5-HT 1B receptor antagonists SB 224289 and the mixed 5-HT 1B/1D receptor antagonist GR 127935 on extracellular levels of 5-HT was unaltered by duration of treatment. Basal levels of 5-HT, however, were increased in the dorsal hippocampus following chronic treatment. In addition, plasma levels of the catecholamines adrenaline and noradrenaline and the HPA axis hormones ACTH and corticosterone were all decreased after chronic treatment.


Asunto(s)
Citalopram/farmacología , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Receptor de Serotonina 5-HT1B/efectos de los fármacos , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Hormona Adrenocorticotrópica/sangre , Animales , Encéfalo/metabolismo , Catecolaminas/sangre , Citalopram/farmacocinética , Corticosterona/sangre , Espacio Extracelular/metabolismo , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Masculino , Microdiálisis , Oxadiazoles/farmacología , Piperazinas/farmacología , Piperidonas/farmacología , Corteza Prefrontal/efectos de los fármacos , Corteza Prefrontal/metabolismo , Ratas , Receptores Presinapticos/efectos de los fármacos , Serotonina/metabolismo , Antagonistas de la Serotonina/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/farmacocinética , Compuestos de Espiro/farmacología
6.
Psychopharmacology (Berl) ; 178(2-3): 151-60, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15448978

RESUMEN

RATIONALE: Male wild house-mice genetically selected for long attack latency (LAL) and short attack latency (SAL) differ in structural and functional properties of postsynaptic serotonergic-1A (5-HT(1A)) receptors. These mouse lines also show divergent behavioral responses in the forced swimming test (FST, i.e., higher immobility by LAL versus SAL mice). OBJECTIVES: We investigated whether the line difference in 5-HT(1A) receptors is associated with a difference in brain 5-HT metabolism, and whether acute administration of a 5-HT(1A) receptor agonist could differentially affect the behavioral responses of LAL and SAL mice. METHODS: 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) levels were measured in homogenates of several brain regions using high-performance liquid chromatography. The behavioral effect of the full 5-HT(1A) receptor agonist, 8-OH-DPAT, and of the somatodendritic 5-HT(1A) autoreceptor agonist, S-15535, was examined in the FST. The effect of 8-OH-DPAT on forced swimming-induced 5-HT metabolism in brain homogenates was determined. RESULTS: In most brain regions, 5-HT and 5-HIAA levels and 5-HT turnover were not significantly different between LAL and SAL mice. 8-OH-DPAT abolished the behavioral line difference in the FST by reducing immobility in LAL mice and reducing climbing in SAL mice. S-15535 induced a similar behavioral effect to 8-OH-DPAT in SAL mice, but did not alter the behavior of LAL mice. Compared with LAL, forced swimming elicited in SAL mice a higher brain 5-HT turnover, which was potently attenuated by 8-OH-DPAT. CONCLUSIONS: It is unlikely that the difference in 5-HT(1A) properties between LAL and SAL mice is an adaptive compensatory reaction to changes in 5-HT metabolism. Although unspecific motor effects, at least in SAL mice, cannot be ruled out, it is suggested that the behavioral effects of 8-OH-DPAT and S-15535 may be mediated by predominant activation of postsynaptic 5-HT(1A) receptors in LAL mice and by presynaptic 5-HT(1A) receptors in SAL mice.


Asunto(s)
Agresión/fisiología , Encéfalo/efectos de los fármacos , Miedo/efectos de los fármacos , Actividad Motora/efectos de los fármacos , Agonistas del Receptor de Serotonina 5-HT1 , Serotonina/metabolismo , 8-Hidroxi-2-(di-n-propilamino)tetralin/farmacología , Adaptación Psicológica/efectos de los fármacos , Conducta Agonística/efectos de los fármacos , Animales , Nivel de Alerta/efectos de los fármacos , Nivel de Alerta/genética , Reacción de Fuga/efectos de los fármacos , Desamparo Adquirido , Inyecciones Intraperitoneales , Masculino , Ratones , Ratones Endogámicos , Piperazinas/farmacología , Tiempo de Reacción/efectos de los fármacos , Tiempo de Reacción/genética , Selección Genética , Agonistas de Receptores de Serotonina/farmacología , Natación
7.
Brain Res Bull ; 61(6): 627-35, 2003 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-14519460

RESUMEN

Neuroimaging studies in patients suffering from affective disorders have shown decreased volume and reduced regional cerebral blood flow in multiple areas of the prefrontal cortex, including the medial prefrontal cortex and the orbitofrontal cortex. This aberrant brain activity is among other things attributed to chronic stress. Affective disorders occur more often in women than in men. In the current experiment, female mPFC-lesioned and non-lesioned rats were subjected to 3 weeks of chronic unpredictable stress in order to determine the role of the mPFC in dealing with chronic stress, and the consequences of mPFC damage for coping with consecutive stressful events. mPFC damage in female rats intensified the stress-induced activation of the dorsomedial nucleus of the hypothalamus and the paraventricular nucleus of the hypothalamus as measured with Fos expression changes and markedly increased plasma catecholamine levels after 3 weeks of unpredictable stress. Additionally, an mPFC lesion significantly reduced the time of appearance of stress-induced behavioral changes in the open field. Altogether, mPFC dysfunction affects the way female rats react to chronic stress, it not only increased the activation of brain regions involved in neuroendocrine and autonomic responses to stress but it also significantly reduced the time of onset of behavioral changes.


Asunto(s)
Corteza Prefrontal/metabolismo , Estrés Fisiológico/metabolismo , Animales , Corticosterona/sangre , Epinefrina/sangre , Femenino , Actividad Motora/fisiología , Norepinefrina/sangre , Ratas , Ratas Wistar
8.
Eur J Pharmacol ; 455(2-3): 109-15, 2002 Nov 29.
Artículo en Inglés | MEDLINE | ID: mdl-12445576

RESUMEN

The consequences of pharmacologically evoked augmented serotonin (5-hydroxytryptamine, 5-HT) release on neuronal activity in the brain, as reflected by the cellular expression of the immediate early gene c-fos, were studied. Wistar rats were treated with saline, the 5-HT reuptake inhibitor citalopram (10 micromol/kg s.c.), the 5-HT(1A) receptor antagonist N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)-N-(2-pyridyl)cyclohexane carboxamine trihydrochloride (WAY 100635, 1 micromol/kg s.c.), or the combination of both drugs. At the given dosages, the combination of the drugs has previously been shown to enhance the cerebral release of 5-HT. Two hours and thirty minutes after administration, the brains were fixated, and Fos protein was histologically stained and quantified. The paraventricular nucleus of the hypothalamus, the central nucleus amygdala, the ventromedial hypothalamic nucleus, the dorsolateral striatum, and the nucleus accumbens shell were particularly responsive to increased 5-HT release. The results, illustrating the synergistic consequence of the combined drug treatments, are discussed in terms of activity of the limbic-hypothalamic-pituitary-adrenocortical system.


Asunto(s)
Encéfalo/metabolismo , Proteínas Proto-Oncogénicas c-fos/biosíntesis , Receptores de Serotonina/fisiología , Serotonina/metabolismo , Animales , Encéfalo/efectos de los fármacos , Citalopram/farmacología , Sinergismo Farmacológico , Inmunohistoquímica , Masculino , Piperazinas/farmacología , Piridinas/farmacología , Ratas , Ratas Wistar , Receptores de Serotonina/efectos de los fármacos , Receptores de Serotonina 5-HT1 , Antagonistas de la Serotonina/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...